Focal Epilepsy Clinical Trials
Here are the 0 most popular medical studies for focal epilepsy
Popular filter options for focal epilepsy trials
Epilepsy Clinical Trials
View 8 Epilepsy medical studies.
Adjunctive Therapy
XEN1101 for Epilepsy
This trial will test if XEN1101 is an effective and safe treatment for focal epilepsy in adults. The trial will be double-blind, meaning neither the patients nor the researchers will know who is receiving the real treatment or the placebo. There will also be an optional open-label extension, meaning that at the end of the trial, patients who wish to can receive the real treatment.
Dravet Syndrome Clinical Trials
View 7 Dravet Syndrome medical studies.
Adjunctive Therapy
XEN1101 for Epilepsy
This trial will test if XEN1101 is an effective and safe treatment for focal epilepsy in adults. The trial will be double-blind, meaning neither the patients nor the researchers will know who is receiving the real treatment or the placebo. There will also be an optional open-label extension, meaning that at the end of the trial, patients who wish to can receive the real treatment.
Clobazam treatment for Epilepsy
The goal of the present study is to obtain pilot data on efficacy and safety of clobazam add-on treatment on adults with drug-resistant focal epilepsy. This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment. 10 adults aged 18-65 with focal seizures that have failed to respond to ≥ 4 antiepileptic drugs (AEDs) +/- respective surgery will be enrolled. Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first. Titration rate will be not be forced. It is anticipated that the majority of subjects will have a 4 week-long titration period. After maximum dose is achieved, maintenance treatment will last for 12 weeks.
Focal Epilepsy Clinical Trials With No Placebo
View 9 focal epilepsy medical studies that do not have a placebo group.
Clobazam treatment for Epilepsy
The goal of the present study is to obtain pilot data on efficacy and safety of clobazam add-on treatment on adults with drug-resistant focal epilepsy. This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment. 10 adults aged 18-65 with focal seizures that have failed to respond to ≥ 4 antiepileptic drugs (AEDs) +/- respective surgery will be enrolled. Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first. Titration rate will be not be forced. It is anticipated that the majority of subjects will have a 4 week-long titration period. After maximum dose is achieved, maintenance treatment will last for 12 weeks.
Procedure
Noninvasive Imaging for Epilepsy
This trial will compare the sensitivities and specificities of morphometric analysis techniques using MRI images to pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy, in order to establish an age-stratified normative imaging database.
Frequently Asked Questions
Introduction to focal epilepsy
What are the top hospitals conducting focal epilepsy research?
When it comes to cutting-edge clinical trials in the field of focal epilepsy, several hospitals have emerged as leaders in their research efforts. In Rochester, Minnesota, the renowned Mayo Clinic is currently conducting three active trials focused on this condition. Over time, they have contributed to a total of six trials dedicated to understanding and treating focal epilepsy since recording their first trial in 2012. Moving down south to Jacksonville, Florida, the University of Florida Jacksonville has also made significant strides with two ongoing focal epilepsy trials and an additional two completed studies since embarking on their inaugural trial in 2019.
Meanwhile, at the University of Virginia in Charlottesville, researchers are actively engaged in two clinical trials targeting focal epilepsy. Their commitment to advancing knowledge about this condition is evident from their previous four conducted studies dating back to 2011. Similarly devoted are the medical professionals at the University of Kansas Medical Center in Kansas City who presently oversee two active focal epilepsy trials while having previously conducted three other valuable investigations beginning with their initial trial in 2009.
Lastly but not least importantly,Vanderbilt University Medical Center located Nashville deserves special mention for its relentless dedication towards combating focal epilepsy through various dimensions where they're recently managing one current clinical tests along with substantial completion records comprising no less than six pivotal scientific inquiries that commenced way back during2006.As these top hospitals continue pushing boundaries and expanding our understanding of focal epilepsy through innovative research initiatives and patient-centered approaches; we can be optimistic that each step taken brings us closer toward enhanced treatment options and improved quality of life for individuals living with this challenging neurological disorder
Which are the best cities for focal epilepsy clinical trials?
When it comes to focal epilepsy clinical trials, several cities emerge as prominent hubs for research and innovation. Philadelphia, Pennsylvania, boasts 5 active trials focusing on treatments like XEN1101, the STARSTIM device, CVL-865, and more. Bethesda, Maryland also offers 5 ongoing studies exploring MRI techniques along with interventions such as CVL-865 and XEN1101. Rochester, Minnesota contributes to this field with 4 active trials investigating devices like the Medtronic Summit System and Olympus in addition to XEN1101 and the STARSTIM device. Lastly, Jacksonville and Baltimore each have 4 active trials studying various treatment options including XEN1101 and the STARSTIM device. These cities provide valuable opportunities for individuals affected by focal epilepsy to participate in cutting-edge clinical trials that may lead to significant advancements in care.
Which are the top treatments for focal epilepsy being explored in clinical trials?
Exciting developments are underway in the field of focal epilepsy, with several top treatments currently being explored through clinical trials. The STARSTIM device, a cutting-edge technology introduced in 2021, is at the forefront, participating in one active trial dedicated to treating focal epilepsy. Another promising contender is Nifedipine, also involved in one ongoing trial since its debut last year. Additionally, the Medtronic Summit System from Olympus and XEN1101 have each contributed to the collective efforts with one active trial apiece for focal epilepsy treatment. These innovative treatments offer hope for individuals affected by this condition as research continues to advance towards improved management and quality of life.
What are the most recent clinical trials for focal epilepsy?
Recent clinical trials in focal epilepsy have shown promising advancements in the search for improved treatments. Nifedipine and CVL-865, both undergoing Phase 2 trials, have emerged as potential options to address this neurological disorder. Additionally, the Medtronic Summit System and Olympus are being studied in a Phase 1 trial for their effectiveness in managing focal epilepsy symptoms. While these studies provide hope for better outcomes, it is important to note that XEN1101 has already completed its Phase 2 trial with encouraging results. Lastly, clobazam treatment is currently undergoing a Phase 4 trial to further evaluate its efficacy against focal epilepsy. These ongoing efforts bring us closer to finding effective interventions that can enhance the quality of life for those affected by focal epilepsy.
What focal epilepsy clinical trials were recently completed?
Recently, several clinical trials investigating focal epilepsy have successfully concluded, bringing new insights and potential treatments to the forefront. These studies aimed to address the unique challenges faced by individuals with this specific type of epilepsy. By focusing on targeted therapies and interventions, researchers strive to improve seizure control and overall quality of life for patients. These innovative trials represent significant progress in our understanding and management of focal epilepsy, offering hope for those affected by this condition.